利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.035 秒)

    CONJUGATE COMPRISING OXYNTOMODULIN AND AN IMMUNOGLOBULIN FRAGMENT, AND USE THEREOF
    3.
    发明申请
    CONJUGATE COMPRISING OXYNTOMODULIN AND AN IMMUNOGLOBULIN FRAGMENT, AND USE THEREOF 有权
    包含氧自由基蛋白和免疫球蛋白片段的连接及其用途

    公开(公告)号：US20140212440A1

    公开(公告)日：2014-07-31

    申请号：US14126914

    申请日：2012-06-15

    申请人： Sung Youb Jung ,  Dae Jin Kim ,  Sung Hee Park ,  Young Eun Woo ,  In Young Choi ,  Se Chang Kwon

    发明人： Sung Youb Jung ,  Dae Jin Kim ,  Sung Hee Park ,  Young Eun Woo ,  In Young Choi ,  Se Chang Kwon

    IPC分类号： A61K47/48 ,  A61K38/26

    CPC分类号： A61K47/6889 ,  A61K38/00 ,  A61K38/26 ,  A61K45/06 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6801 ,  A61K47/6811 ,  C07K14/575 ,  C07K2319/30

    摘要： The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

    摘要翻译： 本发明涉及包含胃泌酸调节蛋白，免疫球蛋白Fc区和非肽基聚合物的缀合物，其中通过非肽基聚合物共价连接胃泌酸调节蛋白与免疫球蛋白Fc区域可获得的缀合物和用于预防或治疗肥胖症的药物组合物 包括缀合物。 与天然胃泌酸调节蛋白不同，包含胃泌酸调节蛋白和本发明的免疫球蛋白Fc的缀合物减少食物摄入，抑制胃排空，并且促进脂肪分解而不具有副作用，并且与天然胃泌酸调节素相比也显示出优异的受体激活作用和长期可持续性 。 因此，可广泛用于治疗肥胖症的安全性和有效性。

    PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING INTERFERON ALPHA CONJUGATE
    6.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING INTERFERON ALPHA CONJUGATE 有权
    用于治疗癌症的药物组合物，包括干扰素ALPHA联合

    公开(公告)号：US20140219961A1

    公开(公告)日：2014-08-07

    申请号：US14342715

    申请日：2012-09-05

    申请人： Sung Youb Jung ,  Young Eun Woo ,  Se Young Lim ,  In Young Choi ,  Jae Ho Lee ,  Se Chang Kwon ,  Sung Hwan Moon ,  Jiawang Liu

    发明人： Sung Youb Jung ,  Young Eun Woo ,  Se Young Lim ,  In Young Choi ,  Jae Ho Lee ,  Se Chang Kwon ,  Sung Hwan Moon ,  Jiawang Liu

    IPC分类号： A61K47/48 ,  A61K31/7068 ,  A61K38/21

    CPC分类号： A61K47/642 ,  A61K9/0019 ,  A61K31/7068 ,  A61K38/212 ,  A61K47/60 ,  A61K47/68

    摘要： A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient.

    摘要翻译： 预防或治疗癌症的方法包括施用包含干扰素α或其聚合物缀合物的抗癌药物组合物。 药物组合物可与抗癌剂共同施用。 干扰素α缀合物显示比常规干扰素α更长的体内半衰期和更优异的抗癌活性，特别是其与抗癌药如吉西他滨的共同给药对癌细胞具有协同抑制作用 生长和增殖，以显示出非常优异的抗癌活性。 此外，抗癌药物组合物具有优异的体内半衰期和抗癌活性，从而大大降低给药频率。 共同施用抗癌剂和具有优异抗癌活性的干扰素α缀合物降低了抗癌剂的施用剂量，从而降低了抗癌剂的副作用并增加了患者的治疗依从性。

    COMPOSITION FOR TREATING DIABETES COMPRISING LONG-ACTING INSULIN CONJUGATE AND LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE
    7.
    发明申请
    COMPOSITION FOR TREATING DIABETES COMPRISING LONG-ACTING INSULIN CONJUGATE AND LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE 审中-公开
    用于治疗包含长效胰岛素结合剂和长效胰岛素诱导性糖尿病的糖尿病的组合物

    公开(公告)号：US20140120120A1

    公开(公告)日：2014-05-01

    申请号：US14123355

    申请日：2012-06-01

    申请人： Young Eun Woo ,  Myung Hyun Jang ,  Young Jin Park ,  Young Kyung Park ,  Chang Ki Lim ,  Se Chang Kwon

    发明人： Young Eun Woo ,  Myung Hyun Jang ,  Young Jin Park ,  Young Kyung Park ,  Chang Ki Lim ,  Se Chang Kwon

    IPC分类号： A61K47/48 ,  A61K38/26 ,  A61K38/28

    CPC分类号： A61K38/26 ,  A61K38/28 ,  A61K47/68 ,  A61K47/6811 ,  A61K47/6883

    摘要： The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved in-vivo duration of efficacy and stability.

    摘要翻译： 本发明涉及一种用于预防或治疗糖尿病的组合物，其包含长效胰岛素缀合物和长效促胰岛素肽缀合物，以及用于治疗糖尿病的治疗方法，更具体地说， 作用胰岛素结合物和长效促胰岛素肽结合物抑制胰岛素治疗引起的体重增加，以及由促胰岛素肽治疗引起的呕吐和恶心，并减少所需的胰岛素剂量，从而显着提高药物依从性。 此外，本发明的长效胰岛素缀合物和长效促胰岛素肽缀合物中的每一种都是通过非肽基连接体将胰岛素或促胰岛素肽与免疫球蛋白Fc区连接而制备的，从而显示出改善的体内持续时间 功效和稳定性。